Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study. - Bahlis, Nizar J.; Zonder, Jeffrey; Karlin, Lionel; Plesner, Torben; Paris, Laura; Wrobel, Tomasz; Hungria, Vania; Besemer, Britta; Crusoe, Edvan; Silkjaer, Trine; Perrot, Aurore; Moreau, Philippe; et al. (Leukemia & Lymphoma, 2025)